Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia

NCT00830674 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT00830674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00830674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
May 31, 2013
Enrollment
42 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked hypophosphatemia